Internal Medicine, Endocrinology, Diabetes, & Metabolism · La Crosse, WI
NPI
1033349246
Since 2009
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
1836 South Ave
La Crosse, WI, 54601
Phone (608) 782-7300
Groups this clinician bills Medicare through
Medicare paid, 2024
$29K
727 services
Medicare patients, 2024
241
Average age 68
Drug cost, 2024
$1.3M
2,947 prescriptions
Company payments, 2025
$167
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rachel L McKenney was code 99214 (office e&m - established), 329 times for 205 patients. In total Rachel L McKenney billed 727 services in 12 codes, and Medicare paid $29K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-02-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 329 | 205 | $61.87 | $20K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 313 | 201 | $11.65 | $3,646 |
| 99205 Office E&M - New | Facility | 13 | 13 | $124.92 | $1,624 |
| 99214 Office E&M - Established | Office | 13 | 11 | $68.13 | $886 |
By year: 2022 $31K for 437 services; 2023 $29K for 398 services; 2024 $29K for 727 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rachel L McKenney prescribed most often to Medicare patients was Levothyroxine Sodium, with 445 prescriptions and refills. In total Rachel L McKenney wrote 2,947 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 445 | 1,231 | 121 | $4,998 |
| Trulicity Dulaglutide | 286 | 370 | 50 | $354K |
| Metformin Hcl Er Metformin Hcl | 139 | 319 | 39 | $1,644 |
| Novolog Flexpen Insulin Aspart | 119 | 253 | 41 | $46K |
| Insulin Glargine-Yfgn Generic | 111 | 251 | 31 | $19K |
| Jardiance Empagliflozin | 91 | 174 | 20 | $101K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 88 | 206 | 29 | $16K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 82 | 214 | 31 | $11K |
| Metformin Hcl Generic | 81 | 227 | 22 | $891 |
| Methimazole Generic | 77 | 172 | 17 | $1,493 |
| Mounjaro Tirzepatide | 67 | 80 | 16 | $83K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 66 | 135 | 17 | $36K |
| Glimepiride Generic | 61 | 144 | 13 | $501 |
| Tresiba Flextouch U-200 Insulin Degludec | 59 | 135 | 16 | $96K |
| Alendronate Sodium Generic | 42 | 100 | 15 | $604 |
Brand drugs: 1,534 claims; generic drugs: 1,116 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rachel L McKenney $167 ($167 in general payments such as food, travel and fees) from 2 companies. The largest payer was Ascendis Pharma Endocrinology Inc with $112.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.